Par Pharmaceutical Companies, Inc., a privately held, US-based specialty pharmaceutical company, has announced that its operating subsidiary, Par Pharmaceutical, Inc. begun shipping 5 mg and 10 mg strengths of rizatriptan benzoate tablets and 5 mg and 10 mg strengths of rizatriptan benzoate orally disintegrating tablets.  

Rizatriptan benzoate tablets and rizatriptan benzoate orally disintegrating tablets are each indicated for the acute treatment of migraine with or without aura in adults and in paediatric patients 6 to 17 years of age.  According to IMS Health data, annual US sales of rizatriptan benzoate total approximately $653 million.

Rizatriptan benzoate is contraindicated in patients with ischemic artery disease or other significant underlying cardiovascular disease, coronary artery vasospasm including Prinzmetal’s angina, history of stroke or transient ischemic attack (TIA), peripheral vascular disease (PVD), ischemic bowel disease, uncontrolled hypertension, recent use of another 5-HT1 agonist, ergotamine-containing medication, or ergot-type medication, hemiplegic or basilar migraine, concurrent administration or recent discontinuation of a MAO-A inhibitor and hypersensitivity to rizatriptan benzoate tablets or rizatriptan benzoate orally disintegrating tablets.

Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary’s two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals.